PainReform Ltd. has announced the completion of a strategic investment in LayerBio, Inc., acquiring a majority equity interest in the company. This investment focuses on advancing LayerBio's OcuRing™-K, a sustained-release drug delivery system aimed at managing pain and inflammation following cataract surgery. OcuRing™-K is a non-opiate, non-steroidal postoperative NSAID drug delivery system that targets the growing demand for 'dropless' solutions in ophthalmic surgery. PainReform and LayerBio plan to initiate the next clinical trial of OcuRing™-K in the U.S., aiming for FDA approval to access a high-volume, reimbursable market. The companies also intend to explore broader ophthalmic applications, including treatments for glaucoma, corneal transplants, and anti-infective uses. Results of the upcoming clinical trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.